

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com


Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months Ended on 31-December-2025.

Sr. No.	Particulars	₹ in Lakhs Except Earnings Per Share Data					
		Quarter Ended			Nine Months Ended		Year Ended
		31/12/2025 (Un-Audited)	30/09/2025 (Un-Audited)	31/12/2024 (Un-Audited)	31/12/2025 (Un-Audited)	31/12/2024 (Un-Audited)	31/03/2025 (Audited)
1	<b>Income</b>						
	A) Revenue From Operations	16,632.20	16,336.39	14,655.17	48,375.26	45,504.70	62,323.01
	B) Other Income	1,514.55	723.21	897.00	3,764.93	2,935.68	2,247.71
	<b>Total Income (1)</b>	<b>18,146.75</b>	<b>17,059.60</b>	<b>15,552.17</b>	<b>52,140.19</b>	<b>48,440.38</b>	<b>64,570.72</b>
2	<b>Expenses</b>						
	A) Cost of Material Consumed	4,768.00	5,719.90	5,015.90	16,584.83	16,000.79	21,393.84
	B) Purchase of Stock-In-Trade	2,502.53	2,172.27	1,860.91	6,257.86	5,379.48	6,854.12
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	325.44	(217.61)	(13.25)	(633.73)	(263.51)	884.00
	D) Employee Benefits Expenses	3,061.79	3,035.60	2,797.78	9,273.07	8,483.39	11,245.42
	E) Finance Costs	29.81	23.07	72.81	73.86	151.60	188.27
	F) Deprecation and Amortisation Expense	372.06	361.90	322.43	1,081.68	967.30	1,289.90
	G) Other Expenses	3,614.88	3,083.39	2,627.49	9,610.38	8,427.12	11,796.31
	<b>Total Expenses (2)</b>	<b>14,674.51</b>	<b>14,178.52</b>	<b>12,684.07</b>	<b>42,247.95</b>	<b>39,146.17</b>	<b>53,651.86</b>
3	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>3,472.24</b>	<b>2,881.08</b>	<b>2,868.10</b>	<b>9,892.24</b>	<b>9,294.21</b>	<b>10,918.86</b>
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
5	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>3,472.24</b>	<b>2,881.08</b>	<b>2,868.10</b>	<b>9,892.24</b>	<b>9,294.21</b>	<b>10,918.86</b>
6	Tax Expense						
	A) Current Tax	601.00	861.90	754.90	1,875.20	1,818.00	2,487.20
	B) Deferred Tax	11.24	(12.45)	(13.34)	357.89	349.47	151.53
	C) Short / (Excess) Tax Provision	0.00	33.23	49.60	33.23	49.60	45.49
7	<b>Net Profit / (Loss) For The Period (5-6)</b>	<b>2,860.00</b>	<b>1,998.40</b>	<b>2,076.94</b>	<b>7,625.92</b>	<b>7,077.14</b>	<b>8,234.64</b>
8	Other Comprehensive Income (Net Of Tax)						
	Items that will not be reclassified to subsequently to profit and loss	2.29	2.29	1.52	6.87	4.58	9.17
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil	Nil	Nil
9	<b>Total Comprehensive Income</b>	<b>2,862.29</b>	<b>2,000.69</b>	<b>2,078.46</b>	<b>7,632.79</b>	<b>7,081.72</b>	<b>8,243.81</b>
10	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97
11	Other Equity						65,163.89
12	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>						
	(a) Basic (In ₹)	14.28	9.98	10.37	38.07	35.33	41.11
	(b) Diluted (In ₹)	14.28	9.98	10.37	38.07	35.33	41.11

**Notes:**

- The above standalone un-audited financial results of the Company for the quarter and nine months ended on December 31, 2025 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, February 12, 2026. The auditor have carried out an limited review of the said financial results.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.

For Lincoln Pharmaceuticals Limited



*Mahendra G. Patel*

Mahendra G. Patel  
Managing Director  
DIN: 00104706

Place: Ahmedabad  
Date: February 12, 2026

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com


Statement of Consolidated Un-Audited Financial Results for the Quarter and Nine Months Ended on 31-December-2025.

Sr. No.	Particulars	₹ in Lakhs Except Earnings Per Share Data					
		Quarter Ended			Nine Months Ended		Year Ended
		31/12/2025 (Un-Audited)	30/09/2025 (Un-Audited)	31/12/2024 (Un-Audited)	31/12/2025 (Un-Audited)	31/12/2024 (Un-Audited)	31/03/2025 (Audited)
1	<b>Income</b>						
	A) Revenue From Operations	16,632.20	16,336.39	14,655.17	48,375.26	45,504.70	62,323.01
	B) Other Income	1,514.55	723.21	897.00	3,764.93	2,935.68	2,247.71
	<b>Total Income (1)</b>	<b>18,146.75</b>	<b>17,059.60</b>	<b>15,552.17</b>	<b>52,140.19</b>	<b>48,440.38</b>	<b>64,570.72</b>
2	<b>Expenses</b>						
	A) Cost of Material Consumed	4,768.00	5,719.90	5,015.90	16,584.83	16,000.79	21,393.84
	B) Purchase of Stock-In-Trade	2,502.53	2,172.27	1,860.91	6,257.86	5,379.48	6,854.12
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	325.44	(217.61)	(13.25)	(633.73)	(263.51)	884.00
	D) Employee Benefits Expenses	3,061.79	3,035.60	2,797.78	9,273.07	8,483.39	11,245.42
	E) Finance Costs	29.81	23.07	72.81	73.86	151.60	188.28
	F) Deprecation and Amortisation Expense	372.06	361.90	322.43	1,081.68	967.30	1,289.90
	G) Other Expenses	3,614.88	3,083.39	2,627.49	9,610.38	8,427.12	11,796.30
	<b>Total Expenses (2)</b>	<b>14,674.51</b>	<b>14,178.52</b>	<b>12,684.07</b>	<b>42,247.95</b>	<b>39,146.17</b>	<b>53,651.86</b>
3	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>3,472.24</b>	<b>2,881.08</b>	<b>2,868.10</b>	<b>9,892.24</b>	<b>9,294.21</b>	<b>10,918.86</b>
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
5	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>3,472.24</b>	<b>2,881.08</b>	<b>2,868.10</b>	<b>9,892.24</b>	<b>9,294.21</b>	<b>10,918.86</b>
6	Tax Expense						
	A) Current Tax	601.00	861.90	754.90	1,875.20	1,818.00	2,487.20
	B) Deferred Tax	11.24	(12.45)	(13.34)	357.89	349.47	151.53
	C) Short / (Excess) Tax Provision	Nil	33.23	49.60	33.23	49.60	45.49
7	<b>Net Profit / (Loss) For The Period (5-6)</b>	<b>2,860.00</b>	<b>1,998.40</b>	<b>2,076.94</b>	<b>7,625.92</b>	<b>7,077.14</b>	<b>8,234.64</b>
8	Attributable to Non-Controlling Interest	Nil	Nil	Nil	Nil	Nil	Nil
	<b>Attributable to Owners of the Company</b>	<b>2,860.00</b>	<b>1,998.40</b>	<b>2,076.94</b>	<b>7,625.92</b>	<b>7,077.14</b>	<b>8,234.64</b>
9	Other Comprehensive Income (Net Of Tax)						
	Items that will not be reclassified to subsequently to profit and loss	2.29	2.29	1.52	6.87	4.58	9.17
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil	Nil	Nil
10	<b>Total Comprehensive Income</b>	<b>2,862.29</b>	<b>2,000.69</b>	<b>2,078.46</b>	<b>7,632.79</b>	<b>7,081.72</b>	<b>8,243.81</b>
11	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97
12	Other Equity						65,163.89
	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>						
13	(a) Basic (In ₹)	14.28	9.98	10.37	38.07	35.33	41.11
	(b) Diluted (In ₹)	14.28	9.98	10.37	38.07	35.33	41.11

**Notes:**

- The above consolidated un-audited financial results of the Company for the quarter and nine months ended on December 31, 2025 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, February 12, 2026. The auditor have carried out an limited review of the said financial results.
- This financial statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.
- Consolidated un-audited financial results includes results of one subsidiary namely Zullinc Healthcare LLP.

For Lincoln Pharmaceuticals Limited



Mahendra G. Patel  
Managing Director  
DIN: 00104706

Place: Ahmedabad  
Date: February 12, 2026